The erythropoietin drugs market was valued at US$13.80 billion in 2022.
Erythropoietin drugs are used to treat anemia, which is a condition characterized by a low number of red blood cells. The erythropoietin stimulating agents (ESAs) are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. ESAs include epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The lower the pO2, the more prominent the creation of EPO. ESAs are for the most part shown in conditions where there is debilitated red platelet creation. Some athletes improperly use EPO drugs to boost their performance because EPO increases the availability of oxygen to their muscles. However, the use of EPO drugs can have serious health consequences as well.
The erythropoietin drugs market is a growing market that deals with the production and distribution of erythropoietin-stimulating agents (ESAs). ESAs are recombinant versions of erythropoietin produced pharmacologically via recombinant DNA technology in cell cultures. The market is driven by the increasing incidence of anaemia, particularly in the ageing population, and the growing demand for biosimilars. The market can be segmented based on drug class, product, application, and geography. Asia Pacific dominates the global erythropoietin drugs market. Key players operating in the erythropoietin drugs market include Mayo Clinic, Weefsel Pharma, Trumac Healthcare, and Incepta Pharmaceuticals Ltd.
Products offered by key companies:
Mayo Clinic offers a range of erythropoietin drugs to treat anemia, including epoetin alfa, darbepoetin, and methoxy polyethylene glycol-epoetin beta. The clinic also provides comprehensive care for patients with anaemia, including diagnosis, treatment, and follow-up care.
Weefsel Pharma's erythropoietin injection is a treatment for anemia caused by kidney disorders and chemotherapy.
Prominent growth in the renal disorders segment within the erythropoietin drugs market:
The erythropoietin drug market is expected to grow steadily in the coming years, driven by the increasing prevalence of anemia caused by end-stage renal disease treatment, chemotherapy, and antiretroviral therapy. The kidney disorders segment (ESRD and dialysis) accounted for a significant share in 2020 and is expected to maintain a strong growth trajectory during the forecast period. The rising incidence of chronic diseases such as cancer, chronic kidney disease (CKD), and HIV is fueling the demand for erythropoietin drugs. However, the introduction of biosimilar erythropoietin (EPO) in the US market in 2018, the impending patent expiry of Aranesp in 2024 in the US, declining prices, and the development of alternative products such as HIF prolyl-hydroxylase inhibitors are moderating the growth of the erythropoietin drugs market. The biologics erythropoietin segment is expected to remain dominant during the forecast period, as patents for these drugs are still in effect.
The Asia Pacific region is expected to hold a significant share of the Erythropoietin drugs market:
The Asia Pacific region is expected to hold a significant share of the erythropoietin drugs market, driven by the rapidly increasing population and the high prevalence of chronic diseases such as cancer and chronic kidney disease (CKD). The region is a promising market for the growth of erythropoietin, and the majority of originator companies for erythropoietin are focusing on the Asia-Pacific market. India and China are major erythropoietin biosimilar markets, and the region demonstrates the largest share of the biosimilar industry, owing to the development of biosimilars by major manufacturers in these regions. The majority of biosimilar manufacturers in Asia-Pacific can afford to launch biosimilar versions of erythropoietin at 25–40% less price than innovator products. The Asia-Pacific and LAMEA regions offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin.
In June 2020, GlaxoSmithKline plc (GSK) secured Japanese regulatory approval for Duvroq (daprodustat), an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), in the treatment of anaemia associated with chronic kidney disease (CKD).
| Report Metric | Details |
|---|---|
| Forecast Unit | Billion |
| Study Period | 2017 to 2029 |
| Historical Data | 2017 to 2020 |
| Base Year | 2021 |
| Forecast Period | 2022 – 2029 |
| Segmentation | Type, Product, Application, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|